



HAL
open science

Perspectives of biomedical application of macrofungi

Susanna M. Badalyan, Sylvie Rapior

► **To cite this version:**

Susanna M. Badalyan, Sylvie Rapior. Perspectives of biomedical application of macrofungi. *Current Trends in Biomedical Engineering & Biosciences*, 2020, 19 (5), pp.556024. 10.19080/CT-BEB.2020.19.556024 . hal-02943347

HAL Id: hal-02943347

<https://hal.umontpellier.fr/hal-02943347v1>

Submitted on 19 Sep 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Perspectives of Biomedical Application of Macrofungi

Susanna M. Badalyan^{1*} and Sylvie Rapior^{2*}

¹Laboratory of Fungal Biology and Biotechnology, Institute of Pharmacy, Department of Biomedicine, Yerevan State University, Yerevan, Armenia

E-mail: s.badalyan@ysu.am

²Laboratoire de Botanique, Phytochimie et Mycologie, Faculté de Pharmacie, CEFE CNRS – Université de Cedex Montpellier – Université Paul-Valéry Montpellier – EPHE – IRD, Montpellier 5, France

E-mail: sylvie.rapior@umontpellier.fr

* Corresponding authors: S.M. Badalyan and S. Rapior

Abstract. Mushrooms (macrofungi) have widely been appreciated all over the world for both their nutritional values and medicinal properties. They have been used in traditional medicine for more than 3000 years for prevention and treatment of different diseases. Modern scientific research shows that mushrooms are producers of a broad spectrum of high- and low-molecular-weight bioactive compounds, i.e., alkaloids, polysaccharides, proteins, phenolics, terpenoids, polyketides, cyclic peptides, lectins and ribosome-inactivating proteins. They have various therapeutic effects as antidiabetic, anti-inflammatory, antimicrobial, antioxidant, anti-tumorous, antiviral, cardioprotective, hepatoprotective, hypocholesterolemic, hypotensive, immunomodulatory, neuroprotective and regenerative activities, and possess promising pharmacological potential. Development of fungal biotechnological cultivation industry will support production of mushroom-derived biotech products, healthy food and pharmaceuticals. Further advances in fungal biology and biotechnology, genomics and proteomics will assist biomedical research and application of mushrooms.

Keywords: medicinal mushrooms, Basidiomycota, Ascomycota, bioactive compounds, pharmacological effect, biomedicine.

Abbreviations: **BAC**, bioactive compounds; **FIP**, fungal immunomodulatory protein; **MM**, medicinal mushrooms.

INTRODUCTION

Fungi are very diverse organisms distributed worldwide and found in almost all habitats. From estimated 1.5-3 million species of fungi about 150,000 species are mushrooms (macrofungi) taxonomically placed in two phyla, the *Basidiomycota* (class *Agaricomycetes*) and *Ascomycota* (class *Pezizomycetes*) in the subkingdom Dikarya [1]. Among the fungal species about 10%

(14,000-16,000) are scientifically well-known including, about 7000 edible species and 500 poisonous species [2,3]. There may be as many as 700 medicinal mushrooms which are regarded safe and possess around 130 different pharmacological activities [4,5].

Mushrooms have widely been appreciated all over the world not only for their nutritional values but also medicinal properties [5-12]. They have been used in traditional medicine for more than 3000 years for prevention and treatment of different diseases [13,14]. Despite available ethnomycopharmacological information and scientific data the extensive pharmacological and biotechnological potential offered by mushrooms is certainly not yet fully exploited [15-20].

BIOACTIVE MOLECULES AND PHARMACOLOGICAL ACTIVITY OF MUSHROOMS

Modern scientific data shows that agaricoid, polyporoid, and other taxonomic groups of mushrooms are producers of a broad spectrum of high- and low-molecular-weight bioactive compounds, i.e., alkaloids, polysaccharides, proteins, phenolics, terpenoids, polyketides, cyclic peptides, lectins, ribosome-inactivating proteins. [21-27] These bioactive molecules were investigated for their various therapeutic effects as analgesic, antimicrobial, antiviral, antioxidant, immunomodulatory, anti-inflammatory, anti-tumorous, mitogenic/regenerative, hypotensive, hepatoprotective, antidiabetic/hypoglycemic, hypocholesterolemic, cardio- and neuroprotective activities [28-45].

Wild and cultivable edible, and non-edible medicinal mushrooms (e.g. *Agaricus brasiliensis*, *Agrocybe cylindracea*, *Auricularia auricula-judae*, *Coprinus comatus*, *Ganoderma applanatum*, *G. lucidum*, *Grifola frondosa*, *Hericium erinaceus*, *Flammulina velutipes*, *Inonotus obliquus*, *Lentinula edodes*, *Ophiocordyceps* (syn. *Cordyceps*) *sinensis*, *Phellinus linteus*, *Pleurotus ostreatus*, *Polyporus umbellatus*, *Trametes versicolor*, *Tremella fuciformis*, *Wolfiporia cocos*, etc.) are considered as valuable sources to develop health enhancing functional food (nutraceuticals, nutraceuticals), mushrooms-derived drugs (mycopharmaceuticals), and cosmetic products (cosmeceuticals, nutricosmetics) which are perspective for biomedical application [12,18-20,46].

A wide spectrum of bioactive molecules with mushrooms origin has been recommended for a variety of therapeutic applications, such as the immunomodulatory β -glucan lentinan from *L. edodes* [27], the antimalarial alkaloid 4-hydroxymethylquinoline from *T. versicolor* [47]; pain-suppressive enkephalinase inhibitors from *Polyporus betulinus* [48]; nephroprotective polysaccharides, phenolics, and flavonoids from *Pleurotus tuber-regium* [37].

The extract derived from well-known medicinal mushrooms *Cordyceps sinensis* and *A. subrufescens* possess anticancer effects by modulating the immune system and inducing cell apoptosis [25,38]. The edible medicinal oyster mushroom *Pleurotus ostreatus* has significant hypocholesterolemic properties and other pharmacological effects [30,39,40,43]. Anticancer,

antimicrobial, antioxidant, antiviral, hypolipidemic, immunomodulatory, and estrogen-like activities were observed in *Pleurotus eryngii* due to the production of diterpenoids, as eryngiolide A, hemolysins, polysaccharides, pentacyclic triterpenoids, ubiquinone-9, and other pharmacologically active biomolecules [43,49,50]. Genome sequencing, comparative genomics, and phylogenetic analysis of medicinal polypore mushroom *Lignosus rhinocerotis* revealed sesquiterpenoid biosynthesis genes. Moreover, the genome of *L. rhinocerotis* encodes for 1,3- β - and 1,6- β -glucans, as well as for laccase, lectin, and other fungal immunomodulatory proteins (FIP) [51,52].

The *Ganoderma* species produce the highest diversity of bioactive compounds (alkaloids, fatty acids, nucleosides, polysaccharides, proteins, sterols, triterpenoids, etc.) with antiaging, antibacterial, anticancer, antidiabetic, antifungal, antihypertensive, anti-inflammatory, antioxidant, antiviral, hepatoprotective, hypoglycemic, immunomodulatory, neuroprotective, wound-healing, and other pharmacological capacities [22,23,32-34,41,42].

CONCLUSION AND FUTURE PERSPECTIVES

Nowadays, pharmaceutical companies consider the medicinal mushrooms as a rich source of innovative biomedical molecules extracted not only from fruiting bodies but also from both cultivated mycelial biomass and cultural broth. Moreover, the mycelium and the cultural broth might be considered as potential sources of bioactive compounds, due to their shorter incubation time and affordable culture conditions (e.g., requiring less space, low probability of contamination, and higher production of biomass) [12,36,43].

The advances in multidimensional biotechnological cultivation industry of mushrooms will further support development and application of mushroom-derived biotech products and pharmaceuticals in biomedicine [7,19,20].

Currently, in vitro assays, animal studies, and clinical trials justify the experience of traditional medicine and suggest a great potential of mushroom-derived compounds and pharmaceuticals for both the prevention and treatment of various diseases. However, development of high-quality mushrooms-based biotech products under controlled conditions with standardized procedures for further clinical trials are needed to substantiate the pharmacological properties or side effects of mushroom consumption before their clinical recommendation as myco-pharmaceuticals [36,53-56]. Compared to available extensive lists of mushrooms' bioactive compounds and therapeutic effects, the pathways of their biosynthesis and the genes behind are largely understudied [19]. Therefore, advances in fungal biology and biotechnology, genomics and proteomics are required for further biomedical research and application of macrofungi.

Acknowledgments This review arises from a long-standing cooperation between two authors (S.M.B. and S.R.) on fungal research directed to the identification of bioactive compounds and medicinal properties supported by the collaboration between the Institute of Pharmacy; Yerevan State University, Armenia; and Faculty of Pharmacy of the University of Montpellier/UMR 5175 CNRS, France. The research project on medicinal mushrooms was partially sponsored by MES SCS Republic of Armenia (grant number #18T-1F115).

References

1. Hibbett DS, Taylor JW (2013) Fungal systematics: is a new age of enlightenment at hand? *Nat Rev Microbiol* 11:129–133.
2. Hawksworth DL (2001) Mushrooms: the extent of the unexplored potential. *Int J Med Mushrooms* 3:333–337.
3. Hawksworth DL (2012) Global species numbers of fungi: are tropical studies and molecular approaches contributing to a more robust estimate? *Biodivers Conserv* 21:2425–2433.
4. Boa ER (2004) Wild edible fungi a global overview of their use and importance to people. Food and Agriculture Organization of the United Nations, Roma.
5. Chang ST, Wasser SP (2017) The cultivation and environmental impact of mushrooms. In: Oxford research encyclopedia of environmental science – Agriculture and the environment. <https://doi.org/10.1093/acrefore/9780199389414.013.231>
6. Chang ST, Miles PG (2008) Mushrooms: Cultivation, nutritional value, medicinal effect, and environmental impact, 2nd edn. CRC Press, Boca Raton.
7. Chang ST, Buswell JA (1996) Mushroom nutraceuticals. *World J Microbiol Biotechnol* 12(5):473–476.
8. Wasser SP (2014) Medicinal mushroom science: current perspectives, advances, evidences, and challenges. *Biomed J.* 37(6):345–356.
9. Valverde ME, Hernández-Pérez T, Paredes-López O (2015) Edible mushrooms: improving human health and promoting quality life. *Intern J Microbiol ID* 376387, 14 p.
10. Gupta S, Summuna B, Gupta M et al (2018) Edible mushrooms: cultivation, bioactive molecules, and health benefits. In: Mérillon JM, Ramawat KG (eds) *Bioactive molecules in food, reference series in Phytochemistry*. Springer, pp 1–33.
11. Bandara AR, Rapior S, Bhat DJ et al (2015) *Polyporus umbellatus*, an edible-medicinal cultivated mushroom with multiple developed health-care products as food, medicine and cosmetics: a review. *Cryptogam Mycol* 36(1):3–42.

12. Bandara AR, Rapior S, Mortimer PE, Kakumyan P, Hyde KD, Xu J (2019) A review of the polysaccharide, protein and selected nutrient content of *Auricularia*, and their potential pharmacological value. *Mycosphere* 10(1):579–607.
13. Hobbs CR (1995) *Medicinal mushrooms: an exploration of traditions, healing, and culture*. Botanica Press, Santa Cruz.
14. Chen H, Tian T, Miao H et al (2016) Traditional uses, fermentation, phytochemistry and pharmacology of *Phellinus linteus*: a review. *Fitoterapia* 113:6–26.
15. Lindequist U (2013) The merit of medicinal mushrooms from a pharmaceutical point of view. *Int J Med Mushrooms* 15(6):517–523.
16. Grienke U, Zöll M, Peintner U et al (2014) European medicinal polypores – a modern view on traditional uses. *J Ethnopharmacol* 154:564–583.
17. De Silva DD, Rapior S, Sudarman E et al (2013) Bioactive metabolites from macrofungi: ethnopharmacology, biological activities and chemistry. *Fungal Divers* 62:1–40.
18. Badalyan SM (2012) Medicinal aspects of edible ectomycorrhizal mushrooms. In: Zambonelli A, Bonito G (eds) *Edible ectomycorrhizal mushrooms, current knowledge and future prospects*, vol 34. Springer-Verlag, Berlin/Heidelberg, pp 317–334.
19. Kües U, Badalyan SM (2017) Making use of genomic information to explore the biotechnological potential of medicinal mushrooms. In: Agrawal DC, Tsay HS, Shyur LF, Wu YC, Wang SY (eds). *Medicinal plants and fungi: recent advances in research and development*. In book series *Medicinal and aromatic plants of the world*. Springer Nature Singapore, pp 397–458.
20. Badalyan SM, Zambonelli A (2019) Biotechnological exploitation of macrofungi for the production of food, pharmaceuticals and cosmeceuticals. In: Sridhar KR, Deshmukh SK (eds) *Advances in macrofungi: diversity, ecology and biotechnology*. Boca Raton, CRC Press, pp 199–230.
21. Xu X, Yan H, Chen J et al (2011) Bioactive proteins from mushrooms. *Biotechnol Adv* 29(6):667–674.
22. Sánchez C (2017) Bioactives from mushrooms and their application. In: Puri M (ed) *Food bioactives*. Springer-Verlag, pp 23–57.
23. Yang YL, Tao QQ, Han JJ et al (2017) Recent advance on bioactive compounds from the edible and medicinal fungi in China. In: Agrawal DC, Tsay HS, Shyur LF, Wu YC, Wang SY (eds) *Medicinal plants and fungi: recent advances in research and development, Medicinal and aromatic plants of the world*. Springer Nature Singapore, pp 253–313.
24. Pandya U, Dhuldhaj U, Sahay NS (2018) Bioactive mushroom polysaccharides as antitumor: an overview. *Nat Prod Res* 4:1–13.

25. Da Silva de Souza AC, Corrêa VG, Goncalves GA et al (2017) *Agaricus blazei* bioactive compounds and their effects on human health: benefits and controversies. *Curr Pharm Des* 23(19):2807–2834.
26. Wang Q, Wang F, Xu Z, Ding Z (2017) Bioactive mushroom polysaccharides: a review on monosaccharide composition, biosynthesis and regulation. *Molecules* 22:955.
27. Novak M, Vetvicka V (2008) β -Glucans, history, and the present: immunomodulatory aspects and mechanisms of action. *J Immunotoxicol* 5(1):47–57.
28. Morel S, Arnould S, Vitou M, Boudard F et al (2018). Antiproliferative and antioxidant activities of wild Boletales mushrooms from France. *Int J Med Mushrooms*, 20(1):13-29.
29. Diallo I, Boudard F, Morel S, Vitou M et al (2020) Antioxidant and anti-inflammatory potential of *Lentinula edodes* (Shiitake) sporophores from various culture conditions. *Int J Med Mushrooms* 22 (in press).
30. Thongbai B, Rapior S, Hyde KD, Wittstein K, Stadler M (2015) *Hericium erinaceus*, an amazing medicinal mushroom. *Mycological Progress* 14(10), Article 91
31. Chen CC, Shiao YJ, Lin RD et al (2006) Neuroprotective diterpenes from the fruiting body of *Antrodia camphorata*. *J Nat Prod* 69:689–691
32. De Silva DD, Rapior S, Fons F et al (2012) Medicinal mushrooms in supportive cancer therapies: an approach to anti-cancer effects and putative mechanisms of action. *Fungal Divers* 55:1–35.
33. De Silva DD, Rapior S, Hyde KD et al (2012) Medicinal mushrooms in prevention and control of diabetes mellitus. *Fungal Divers* 56:1–29.
34. Perera PK, Li Y (2011) Mushrooms as a functional food mediator in preventing and ameliorating diabetes. *Funct Food Health Dis* 4:161–171.
35. Xu H, Kong YY, Chen X et al (2016) Recombinant FIP-gat, a fungal immunomodulatory protein from *Ganoderma atrum*, induces growth inhibition and cell death in breast cancer cells. *J Agric Food Chem* 64:2690–2698.
36. Hyde KD, Jianchu Xu, Rapior S, Lumyong S et al (2019) The amazing potential of fungi, 50 ways we can exploit fungi industrially. *Fungal Diversity Online*, 1–136.
37. Okolo KO, Orisakwe OE, Siminialayi IM (2018) Nephroprotective and antioxidant effects of king tuber oyster medicinal mushroom, *Pleurotus tuberregium* (Agaricomycetes), on carbon tetrachloride-induced nephrotoxicity in male Sprague dawley rats. *Int J Med Mushrooms* 20(5):419–429.
38. Xu J, Huang Y, Chen XX et al (2016) The mechanisms of pharmacological activities of *Ophiocordyceps sinensis* fungi. *Phytother Res* 30:1572–1583.

39. Patel Y, Naraian R, Singh VK (2012) Medicinal properties of *Pleurotus* species (oyster mushroom): a review. *World J Fungal Plant Biol* 3:1–12.
40. Schillaci D, Cusimano MG, Cascioferro SM et al (2017) Antibacterial activity of desert truffles from Saudi Arabia against *Staphylococcus aureus* and *Pseudomonas aeruginosa*. *Int J Med Mushrooms* 19(2):121–125.
41. Saltarelli R, Ceccaroli P, Buffalini M et al (2015) Biochemical characterization, antioxidant and antiproliferative activities of different *Ganoderma* collections. *J Mol Microbiol Biotechnol* 25(1):16–25.
42. Wang XL, Ding ZY, Zhao Y et al (2017) Efficient accumulation and in vitro antitumor activities of triterpene acids from submerged batch-cultured Lingzhi or Reishi medicinal mushroom, *Ganoderma lucidum* (Agaricomycetes). *Int J Med Mushrooms* 19(5):419–431.
43. Zhang C, Li S, Zhang J et al (2016) Antioxidant and hepatoprotective activities of intracellular polysaccharide from *Pleurotus eryngii* SI-04. *Int J Biol Macromol* 91:568–577.
44. Taofiq O, Martins A, Barreiro MF et al (2016) Anti-inflammatory potential of mushroom extracts and isolated metabolites. *Trends Food Sci Technol* 50:193–210.
45. Souilem F, Fernandes Â, Calhella RC et al (2017) Wild mushrooms and their mycelia as sources of bioactive compounds: antioxidant, anti-inflammatory and cytotoxic properties. *Food Chem* 230:40–48.
46. Taofiq O, González-Paramás AM, Martins A et al (2016) Mushrooms extracts and compounds in cosmetics, cosmeceuticals and nutricosmetics – a review. *Ind Crop Prod* 90:38–48.
47. Liu JK (2005) N-containing compounds of macromycetes. *Chem Rev* 105(7):2723–2744.
48. Rathee S, Rathee D, Rathee D et al (2012) Mushrooms as therapeutic agents. *Bras J Pharmacognosy* 22(2):459–474.
49. Ma G, Yang W, Mariga AM et al (2014) Purification, characterization and antitumor activity of polysaccharides from *Pleurotus eryngii* residue. *Carbohydr Polym* 114:297–305.
50. Yen MT, Chang YH, Huang SJ et al (2018) Extraction of ergothioneine from *Pleurotus eryngii* and *P. citrinopileatus* (Agaricomycetes) and preparation of its product. *Int J Med Mushrooms* 20(4):381–392.
51. Yap HY, Chooi YH, Firdaus-Raih M et al (2014) The genome of the tiger milk mushroom, *Lignosus rhinocerotis*, provides insights into the genetic basis of its medicinal properties. *BMC Genomics* 15:635.
52. Yap HY, Fung SY, Ng ST et al (2015) Genome-based proteomic analysis of *Lignosus rhinocerotis* (Cooke) Ryvar den sclerotium. *Int J Med Sci* 12:23–31.
53. Money NP (2016) Are mushrooms medicinal? *Fungal Biol* 120:449–453.

54. Wasser SP (2017) Medicinal mushrooms in human clinical studies. Part I. Anticancer, oncoimmunological, and immunomodulatory activities: a review. *Int J Med Mushrooms* 19(4):279–317.
55. Badalyan SM, Barkhudaryan A, Rapior S (2019) Recent progress in research on the pharmacological potential of mushrooms and prospects for their clinical application. In: Agrawal DC & Dhanasekaran M. (eds) *Medicinal Mushrooms: Recent Progress in Research and Development*. Springer Nature Singapore, pp 1-70.
56. Zmitrovich IV, Belova NV, Balandaykin ME, Bondartseva MA, Wasser SP (2019) Cancer without pharmacological illusions and a niche for Mycotherapy (review). *Int J Med Mushrooms* 21(2):105–119.